BioSpace News Archive

Sage Therapeutics today announced that, on November 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 15,400 shares of its common stock to 12 new employees under Sage’s 2016 Inducement Equity Plan.

Jardiance (empagliflozin) was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors

NeoTract today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH).

Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST

Each shareholder of record of the Company as of the close of business on the Record Date will receive six additional shares for each share held on such date.

Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team and will play a central role in planning and executing the company’s projected launch of the Tack Endovascular System® in 2019.

Omeros Corporation today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.

The Reporting Period represents another successful period of advancements for Invitrocue.

The new Biologics Center will be one of the largest in northern China

Grünenthal had already acquired exclusive commercial rights for Europe, Middle East and Africa in December 2016.